BIOMARKER:

EGFR exon 19 mutation

Entrez ID:

Related biomarkers:

‹

›

EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	icotinib Sensitive: B - Late Trials Respiratory Medicine - 2 weeks
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A2 - Guideline
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: B - Late Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	bevacizumab + erlotinib Sensitive: C3 – Early Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: C3 – Early Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C3 – Early Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	cisplatin + gefitinib + docetaxel Sensitive: C3 – Early Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	erlotinib Sensitive: C4 – Case Studies
EGFR exon 19 mutation EGFR exon 19 mutation	Small Cell Lung Cancer Small Cell Lung Cancer	osimertinib Sensitive: C4 – Case Studies